ETC
IBRX icon

Exchange Traded Concepts’s ImmunityBio IBRX Stock Holding History

Exchange Traded Concepts’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43,776
Closed -$132K – 1454
2025
Q1 		$132K Sell
43,776
-4,208
-9% -$12.8K ﹤0.01% 1069
2024
Q4 		$123K Hold
47,984
– – ﹤0.01% 1108
2024
Q3 		$179K Buy
47,984
+3,722
+8% +$17.2K ﹤0.01% 997
2024
Q2 		$280K Sell
44,262
-13,770
-24% -$90.8K 0.01% 834
2024
Q1 		$312K Sell
58,032
-19,854
-25% -$89.9K 0.01% 784
2023
Q4 		$391K Buy
77,886
+19,750
+34% +$62K 0.01% 716
2023
Q3 		$98.3K Buy
58,136
+10,596
+22% +$21.3K ﹤0.01% 902
2023
Q2 		$132K Buy
+47,540
New +$134K ﹤0.01% 884

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Exchange Traded Concepts's IBRX Position: Q2 2025 in Review

Exchange Traded Concepts sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 43,776 shares — an estimated $132K sold.

Exchange Traded Concepts first reported a position in IBRX in Q2 2023 and held it in 8 quarters. The position peaked at $391K in Q4 2023. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

  • Exchange Traded Concepts reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 43,776 ImmunityBio shares in Q2 2025, an estimated $132K.
  • Exchange Traded Concepts first reported a position in ImmunityBio in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's ImmunityBio position peaked at $391K in Q4 2023.
  • 241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.